Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · October 11, 2023

Long-Term Outcomes of 9-Week vs 1-Year Trastuzumab for Early HER2-Positive Breast Cancer

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial
J. Clin. Oncol 2023 Sep 25;[EPub Ahead of Print], P Conte, G Bisagni, F Piacentini, S Sarti, S Minichillo, E Anselmi, M Aieta, V Gebbia, A Schirone, A Musolino, O Garrone, A Beano, A Rimanti, F Giotta, A Turletti, F Miglietta, MV Dieci, R Vicini, S Balduzzi, R D'Amico, V Guarneri

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading